Alexey A. Lugovskoy, Ph.D.

Dr. Lugovskoy is the President and CEO of Diagonal Therapeutics and Entrepreneur in Residence at Atlas Venture. During his 20+ year career in biotechnology, he guided multiple oncology, autoimmunity, and rare disease programs into the clinic serving as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, Vice President of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Dr. Lugovskoy is an author of over 100 patents and manuscripts, and he is an Associate Editor of the mAbs, a journal dedicated to the art and science of antibody R&D. He received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.